Zobrazeno 1 - 10
of 375
pro vyhledávání: '"Janice P. Dutcher"'
Autor:
Caitlin C. Murphy, Hannah M. Fullington, David E. Gerber, Isaac Alex Bowman, Maneka Puligandla, Janice P. Dutcher, Robert S. DiPaola, Naomi B. Haas
Publikováno v:
Cancer Medicine, Vol 10, Iss 17, Pp 5917-5924 (2021)
Abstract Background As use of oral cancer therapies increases, patient adherence has become critical when evaluating the effectiveness of therapy. In a phase III trial for renal cell carcinoma, we: (a) characterized adherence to sorafenib, sunitinib,
Externí odkaz:
https://doaj.org/article/dba4739510324da8974b70634cac917c
Autor:
Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable resp
Externí odkaz:
https://doaj.org/article/2501d6126ef24a80bcbed81058801563
Autor:
Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong, Janice P. Dutcher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evalua
Externí odkaz:
https://doaj.org/article/10b65dd26def43998f2aa87eba83b4f1
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 5 (2017)
Rituximab (R), a chimeric monoclonal antibody targeting CD20 antigen on B-cells, has become a standard of care in the treatment of B-cell malignancies, most often in conjunction with cytotoxic chemotherapy. Activity has been demonstrated in many subt
Externí odkaz:
https://doaj.org/article/e1b91f9dc13f4319b79525ed531d5420
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 4 (2016)
A 61-year-old woman with metastatic renal cell carcinoma underwent systemic treatment with high-dose interleukin-2 (IL-2). Anemia requiring transfusion of 1 unit of packed red blood cells (PRBCs) was required during the second week of IL-2 therapy. O
Externí odkaz:
https://doaj.org/article/e05d1e6e4cc74401918d4ea231b473ff
Autor:
Janice P. Dutcher
Publikováno v:
Therapeutic Advances in Urology, Vol 5 (2013)
Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the
Externí odkaz:
https://doaj.org/article/c9e83f60b4ce491483bf2cc67288c93e
Autor:
Rupal S. Bhatt, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith Flaherty, Naomi B. Haas, Michael B. Atkins, David F. McDermott, Daniel Tamasauskas, Andrea J. Bullock, Judith Manola, Maneka Puligandla, Wenxin Xu
Purpose:The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR TKIs on circulating cytokines in the ECOG-ACRIN 2805 (ASSURE) trial.Experimental Design:Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd626d06e452000fdcaf81cee5a3311c
https://doi.org/10.1158/1078-0432.c.6528116
https://doi.org/10.1158/1078-0432.c.6528116
Autor:
Rupal S. Bhatt, Venkata Sabbisetti, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith T. Flaherty, Naomi B. Haas, Brian Halbert, Mäneka Puligandla, Wenxin Xu
Distribution of baseline KIM-1 values
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c2cdee842352ce2986ce70fb8469fe7
https://doi.org/10.1158/1078-0432.22479431.v1
https://doi.org/10.1158/1078-0432.22479431.v1
Autor:
Rupal S. Bhatt, Venkata Sabbisetti, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith T. Flaherty, Naomi B. Haas, Brian Halbert, Mäneka Puligandla, Wenxin Xu
Purpose:No circulating biomarkers are currently available to identify patients at highest risk of recurrence after nephrectomy for renal cell carcinoma (RCC). Kidney injury molecule-1 (KIM-1) is overexpressed in RCC and its ectodomain circulates in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::023abce43b4ba67ffd9261175ea90100
https://doi.org/10.1158/1078-0432.c.6530219.v1
https://doi.org/10.1158/1078-0432.c.6530219.v1
Autor:
Rupal S. Bhatt, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith Flaherty, Naomi B. Haas, Michael B. Atkins, David F. McDermott, Daniel Tamasauskas, Andrea J. Bullock, Judith Manola, Maneka Puligandla, Wenxin Xu
Supplemental Table 1: Catalog numbers for MSD assays Supplemental Figure 1: Hazard ratio for CXCL10 and DFS by treatment arm Supplemental Figure 2: Assessment of log-linearity for relationship between IP-10 and recurrence risk Supplemental Table 2: M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22725f540ce6119fca43b206fae8c846
https://doi.org/10.1158/1078-0432.22472090.v1
https://doi.org/10.1158/1078-0432.22472090.v1